---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-122426"
form_type: "8-K"
ticker: null
cik: "0001061027"
company_name: "Viracta Therapeutics, Inc."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:17:46.182045+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Viracta cuts 42% of staff, reduces board to 6; focuses on Nana-val PTCL program

## Summary
- Workforce reduction of ~42% to conserve resources for Nana-val development; expects $0.7M in severance costs.
- Four directors (Barlow, Chung, Murphy, Rubino) resigned Oct 31; board size reduced from 10 to 6 seats.
- Company prioritizing Nana-val for R/R EBV-positive PTCL toward potential NDA submission.
- Actions intended to reduce cash burn and streamline operations; remaining board includes Chairman Pomerantz.

## SEC filing metadata
- accession: 0000950170-24-122426
- form_type: 8-K
- cik: 0001061027
- company_name: Viracta Therapeutics, Inc.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.05, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1061027/000095017024122426/0000950170-24-122426-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1061027/000095017024122426/virx-20241031.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-122426
- JSON: https://secwatch.observer/filing/0000950170-24-122426.json
- Plain text: https://secwatch.observer/filing/0000950170-24-122426.txt

## Key facts
- Executive change
  Jane F. Barlow resigned as Director at Viracta Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: On October 31, 2024, each of Jane F. Barlow, M.D., Jane Chung, R.Ph., Sam Murphy, Ph.D., and Stephen Rubino, Ph.D. notified the Company of their respective resignation as a member of the Board of Directors (the “Board) of the Company, and from all committees of the Board on which they served, in each case effective as of October 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1061027/000095017024122426/0000950170-24-122426-index.htm
- Executive change
  Stephen Rubino resigned as Director at Viracta Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: On October 31, 2024, each of Jane F. Barlow, M.D., Jane Chung, R.Ph., Sam Murphy, Ph.D., and Stephen Rubino, Ph.D. notified the Company of their respective resignation as a member of the Board of Directors (the “Board) of the Company, and from all committees of the Board on which they served, in each case effective as of October 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1061027/000095017024122426/0000950170-24-122426-index.htm
- Executive change
  Sam Murphy resigned as Director at Viracta Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: On October 31, 2024, each of Jane F. Barlow, M.D., Jane Chung, R.Ph., Sam Murphy, Ph.D., and Stephen Rubino, Ph.D. notified the Company of their respective resignation as a member of the Board of Directors (the “Board) of the Company, and from all committees of the Board on which they served, in each case effective as of October 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1061027/000095017024122426/0000950170-24-122426-index.htm
- Executive change
  Jane Chung resigned as Director at Viracta Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: On October 31, 2024, each of Jane F. Barlow, M.D., Jane Chung, R.Ph., Sam Murphy, Ph.D., and Stephen Rubino, Ph.D. notified the Company of their respective resignation as a member of the Board of Directors (the “Board) of the Company, and from all committees of the Board on which they served, in each case effective as of October 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1061027/000095017024122426/0000950170-24-122426-index.htm
- Restructurings & Charges
  Viracta Therapeutics, Inc. announced a restructuring with charges of approximately $0.7 million in total expenses for severance and related benefits for employees impacted by the reduction in force affecting Workforce reduction affecting approximately 42% of the Company's workforce (approximately 42% of the Company's workforce).
  - Type: restructuring
  - Charge: approximately $0.7 million in total expenses for severance and related benefits for employees impacted by the reduction in force
  - Affected area: Workforce reduction affecting approximately 42% of the Company's workforce
  - Headcount: approximately 42% of the Company's workforce
  source text: On October 31, 2024, Viracta Therapeutics, Inc. (the “Company”), committed to and implemented a reduction in force that impacted approximately 42% of the Company’s workforce. The Company expects to recognize approximately $0.7 million in total expenses for severance and related benefits for employees impacted by the reduction in force, consisting primarily of severance payments and related benefits.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1061027/000095017024122426/0000950170-24-122426-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.